Epithelial to mesenchymal transition (EMT) is among the procedures that facilitate GBM metastasis and resistance to chemotherapy. regular brain tissue examples. High-SRPX2 expression amounts are correlated with poor prognosis in those sufferers, aswell as level of resistance to temozolomide in cultured GBM cells. Up-regulating SRPX2 appearance in cultured GBM cell lines facilitated invasiveness and migration of GBM cells, while down-regulating SRPX2 through RNA interference was inhibitory. These results suggest that SRPX2 plays an important role in GBM metastasis. Epithelial to mesenchymal transition (EMT) is one of the processes that facilitate GBM metastasis and resistance to chemotherapy. EMT marker expression was decreased in SRPX2 down-regulated GBM cells, and MAPK signaling pathway marker expression was also decreased when SRPX2 is usually knocked down in GBM-cultured cells. Blocking the MAPK signaling pathway inhibited GBM metastasis but did not inhibit cell invasion and migration in SRPX2 down-regulated cells. Our results indicate that SRPX2 facilitates GBM metastasis by enhancing the EMT process via the MAPK signaling pathway. Keywords:SRPX2, Glioblastoma, EMT, MAPK signaling pathway == Introduction == Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor in adults. It is classified by the World Health Organization as a grade IV tumor of the central nervous system (CNS) (WHO classification tumors of the CNS) (Kurosawa et al.1999). Until recently, complete surgical resection of these infiltrative tumors was virtually impossible. Concurrent adjuvant radiotherapy in combination with temozolomide (TMZ) is the standard of care for patients with newly diagnosed GBM, but less than 5 % of patients survive for longer than 5 years after diagnosis. GBM tumors are among the most resistant of tumors to radiation and cytotoxic chemotherapy. Epithelial to mesenchymal transition (EMT) is considered an important factor that contributes to GBM resistance by diminishing molecular targets (Laure and Bellacosa2005). EMT Top1 inhibitor 1 is usually a common process that takes part in organ development, wound healing, tissue remodeling, cancer progression, and metastasis. The main features accompanying EMT are loss of epithelial characteristics of cells and acquisition of mesenchymal markers such as fibronectin, vimentin, and N-cadherin. As a result, EMT increases the invasiveness and migratory potential of tumor cells, supports their malignant transformation, and might lead to resistance of tumor cells to various therapeutic agents, especially in malignant gliomas. sushi repeat-containing protein, X-linked 2 (SRPX2) was first identified as sushi repeat protein up-regulated leukemia (SRPUL) and is a downstream molecule of the E2A-HLF fusion gene in t(17;19)-positive leukemia Top1 inhibitor 1 cells. SRPX2 contains 3 sushi domains and 1 hyaline domain name. A sushi domain name, also known as a complement control protein module or a short complement-like repeat, contains ~60 amino acids and is found in functionally diverse proteins, including regulators of the complement activation family, the GABA receptor, thyroid peroxidase, and the selectin family (OLeary et al.2004; Soares et al.2005). Sushi domains are thought to mediate specific proteinprotein and/or proteincarbohydrate binding and cellular adhesive functions (OLeary et al.2004; Soares et al.2005). SRPX2 also contains a hyaline (HYR) domain name, which probably corresponds to a newly discovered superfamily in the immunoglobulin fold. The HYR domains are often associated with sushi domains, and although the function of HYR domains is usually unclear, they are thought to be involved in cellular adhesion. Thus, accumulating information around the motifs found in SRPX2 suggest that SRPX2 is usually involved in cellular adhesion. SRPX2 was reported to contribute to the progression and metastasis of variety types of cancers, including gastric, colorectal, and gastrointestinal (Tanaka et al.2009,2012; Liu et al.2015). We hypothesize that SRPX2 also contributes to Top1 inhibitor 1 GBM progression and metastasis. Considering its role in cellular adhesion, SRPX2 is very likely to facilitate GBM metastasis by enhancing the EMT process. To test this hypothesis, we investigated SRPX2 expression levels in GBM tissue samples from 42 patients, as well as in cultured GBM cell lines. We also explored the expression level changes of EMT process markers in SRPX2 down-regulated GBM cells and were the first to document the involvement of SRPX2 in the EMT process and GBM metastasis. == Materials and Methods == == Patients == All investigations in this study were conducted according to the guidelines of the ethics committee of the Third Affiliated Hospital of Harbin Medical University, China. Informed consent was obtained from 42 patients with glioblastoma (GBM, WHO grade 4) who were randomly recruited. Fresh frozen primary GBM samples and paired normal brain tissues were obtained from the Department.Migration (e) and invasion (f) assays in U87MG cells (Vector, SRPX2 siRNA, SRPX2+PD098059, and control siRNA+PD098059) (**p<0.01) == Fig.7. metastasis. Our results revealed that GBM tumor samples from 42 patients expressed higher levels of SRPX2 than the control normal brain tissue samples. High-SRPX2 expression levels are correlated with poor prognosis in those patients, as well as resistance to temozolomide in cultured GBM cells. Up-regulating SRPX2 expression in cultured GBM cell lines facilitated invasiveness and migration of GBM cells, while down-regulating SRPX2 through RNA interference was inhibitory. These results suggest that SRPX2 plays an important role in GBM metastasis. Epithelial to mesenchymal transition (EMT) is one of the processes that facilitate GBM metastasis and resistance to chemotherapy. EMT marker expression was decreased in SRPX2 down-regulated GBM cells, and MAPK signaling pathway marker expression was also decreased when SRPX2 is knocked down in GBM-cultured cells. Blocking the MAPK signaling pathway inhibited GBM metastasis but did not inhibit cell invasion and migration in SRPX2 down-regulated cells. Our results indicate that SRPX2 facilitates GBM metastasis by enhancing the EMT process via the MAPK signaling pathway. Keywords:SRPX2, Glioblastoma, EMT, MAPK signaling pathway == Introduction == Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor in adults. It is classified by the World Health Organization as a grade IV tumor of the central nervous system (CNS) (WHO classification tumors of the CNS) (Kurosawa et al.1999). Until recently, complete surgical resection of these infiltrative tumors was virtually impossible. Concurrent adjuvant radiotherapy in combination with temozolomide (TMZ) is the standard of care for patients with newly diagnosed GBM, but less than 5 % of patients survive for longer than 5 years after diagnosis. GBM tumors are among the most resistant of tumors to radiation and cytotoxic chemotherapy. Epithelial to mesenchymal transition (EMT) is considered an important factor that contributes to GBM resistance by diminishing molecular targets (Laure and Bellacosa2005). EMT is a common process that takes part in organ development, wound healing, tissue remodeling, cancer progression, and metastasis. The main features accompanying EMT are loss of epithelial characteristics of cells and acquisition of mesenchymal markers such as fibronectin, vimentin, and N-cadherin. As a result, EMT increases the invasiveness and migratory potential of tumor cells, supports their malignant transformation, and might lead to resistance of tumor cells to various therapeutic agents, especially in malignant gliomas. sushi repeat-containing protein, X-linked 2 (SRPX2) was first identified as sushi repeat protein up-regulated leukemia (SRPUL) and is a downstream molecule of the E2A-HLF fusion gene in t(17;19)-positive leukemia cells. SRPX2 contains 3 sushi domains and 1 hyaline domain. A sushi domain, also known as a complement control protein module or a short complement-like Rabbit polyclonal to HER2.This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases.This protein has no ligand binding domain of its own and therefore cannot bind growth factors.However, it does bind tightly to other ligand-boun repeat, contains ~60 amino acids and is found in functionally diverse proteins, including regulators of the complement activation family, the GABA receptor, thyroid peroxidase, and the selectin family (OLeary et al.2004; Soares et al.2005). Sushi domains are thought to mediate specific proteinprotein and/or proteincarbohydrate binding and cellular adhesive functions (OLeary et al.2004; Soares et al.2005). SRPX2 also contains a hyaline (HYR) domain, which probably corresponds to a newly discovered superfamily in the immunoglobulin fold. The HYR domains are often associated with sushi domains, and although the function of HYR domains is unclear, they are thought to be involved in cellular adhesion. Thus, accumulating information on the motifs found in SRPX2 suggest that SRPX2 is involved in cellular adhesion. SRPX2 was reported to contribute to the progression and metastasis of variety types of cancers, including gastric, colorectal, and gastrointestinal (Tanaka et al.2009,2012; Liu et al.2015). We hypothesize that SRPX2 also contributes to GBM progression and metastasis. Considering its role in cellular adhesion, SRPX2 is very likely to facilitate GBM metastasis by enhancing the EMT process. To test this hypothesis, we investigated SRPX2 expression levels.Fresh frozen primary GBM samples and paired normal brain tissues were obtained from the Department of Neurosurgery, Third Affiliated Hospital of Harbin Medical University. Glioma initiating cell isolation was performed as described previously (Jiao et al.2015). Epithelial to mesenchymal transition (EMT) is one of the processes that facilitate GBM metastasis and resistance to chemotherapy. EMT marker expression was decreased in SRPX2 down-regulated GBM cells, and MAPK signaling pathway marker expression was also decreased when SRPX2 is knocked down in GBM-cultured cells. Blocking the MAPK signaling pathway inhibited GBM metastasis but did not inhibit cell invasion and migration in SRPX2 down-regulated cells. Our results indicate that SRPX2 facilitates GBM metastasis by enhancing the EMT process via the MAPK signaling pathway. Keywords:SRPX2, Glioblastoma, EMT, MAPK signaling pathway == Introduction == Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor in adults. It is classified by the World Health Organization as a grade IV tumor of the central nervous system (CNS) (WHO classification tumors of the CNS) (Kurosawa et al.1999). Until recently, complete surgical resection of these infiltrative tumors was virtually impossible. Concurrent adjuvant radiotherapy in combination with temozolomide (TMZ) is the standard of care for patients with newly diagnosed GBM, but less than 5 % of patients survive for longer than 5 years after diagnosis. GBM tumors are among the most resistant of tumors to radiation and cytotoxic chemotherapy. Epithelial to mesenchymal transition (EMT) is considered an important factor that contributes to GBM resistance by diminishing molecular targets (Laure and Bellacosa2005). EMT is a common process that takes part in organ development, wound healing, tissue remodeling, cancer progression, and metastasis. The main features accompanying EMT are loss of epithelial characteristics of cells and acquisition of mesenchymal markers such as fibronectin, vimentin, and N-cadherin. As a result, EMT increases the invasiveness and migratory potential of tumor cells, supports their malignant transformation, and might lead to resistance of tumor cells to various therapeutic agents, especially in malignant gliomas. sushi repeat-containing protein, X-linked 2 (SRPX2) was first identified as sushi repeat protein up-regulated leukemia (SRPUL) and is a downstream molecule of the E2A-HLF fusion gene in t(17;19)-positive leukemia cells. SRPX2 contains 3 sushi domains and 1 hyaline domain. A sushi domain, also known as a complement control protein module or a short complement-like repeat, contains ~60 amino acids and is found in functionally diverse proteins, including regulators of the complement activation family, the GABA receptor, thyroid peroxidase, and the selectin family (OLeary et al.2004; Soares et al.2005). Sushi domains are thought to mediate specific proteinprotein and/or proteincarbohydrate binding and cellular adhesive functions (OLeary et al.2004; Soares et al.2005). SRPX2 also contains a hyaline (HYR) domain, which probably corresponds to a newly discovered superfamily in the immunoglobulin fold. The HYR domains are often associated with sushi domains, and although the function of HYR domains is unclear, they are thought to be involved in cellular adhesion. Thus, accumulating information on the motifs found in SRPX2 suggest that SRPX2 is involved in cellular adhesion. SRPX2 was reported to contribute to the progression and metastasis of variety types of cancers, including gastric, colorectal, and gastrointestinal (Tanaka et al.2009,2012; Liu et al.2015). We hypothesize that SRPX2 also contributes to GBM progression and metastasis. Considering its role in cellular adhesion, SRPX2 is very likely to facilitate GBM metastasis by enhancing the EMT process. To test this hypothesis, we investigated SRPX2 expression levels in GBM tissue samples from 42 patients, as well as in cultured GBM cell lines. We also explored the expression level changes of EMT process markers in SRPX2 down-regulated GBM cells and were the first to document the involvement of SRPX2 in the EMT process and GBM metastasis. == Materials and Methods == == Patients == All investigations in this study were conducted according to the guidelines of the ethics committee of the Third Affiliated Hospital of Harbin Medical University or college, China. Informed consent was from 42 individuals with glioblastoma (GBM, WHO grade 4).Epithelial to mesenchymal transition (EMT) is among the procedures that facilitate GBM metastasis and resistance to chemotherapy. regular brain tissue examples. High-SRPX2 expression amounts are correlated with poor prognosis in those sufferers, aswell as level of resistance Odiparcil to temozolomide in cultured GBM cells. Up-regulating SRPX2 appearance in cultured GBM cell lines facilitated invasiveness and migration of GBM cells, while down-regulating SRPX2 through RNA interference was inhibitory. These results suggest that SRPX2 plays an important role in GBM metastasis. Epithelial to mesenchymal transition (EMT) is one of the processes that facilitate GBM metastasis and resistance to chemotherapy. EMT marker expression was decreased in SRPX2 down-regulated GBM cells, and MAPK signaling pathway marker expression was also decreased when SRPX2 is usually knocked down in GBM-cultured cells. Blocking the MAPK signaling pathway inhibited GBM metastasis but did not inhibit cell invasion and migration in SRPX2 down-regulated cells. Our results indicate that SRPX2 facilitates GBM metastasis by enhancing the EMT process via the MAPK signaling pathway. Keywords:SRPX2, Glioblastoma, EMT, MAPK signaling pathway == Introduction == Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor in adults. It is classified by the World Health Organization as a grade IV tumor of the central nervous system (CNS) (WHO classification tumors of the CNS) (Kurosawa et al.1999). Until recently, complete surgical resection of these infiltrative tumors was virtually impossible. Concurrent adjuvant radiotherapy in combination with temozolomide (TMZ) is the standard of care for patients with newly diagnosed GBM, but less than 5 % of patients survive for longer than 5 years after diagnosis. GBM tumors are among the most resistant of tumors to radiation and cytotoxic chemotherapy. Epithelial to mesenchymal transition (EMT) is considered an important factor that contributes to GBM resistance by diminishing molecular targets (Laure and Bellacosa2005). EMT is usually a common process that takes part in organ development, wound healing, tissue remodeling, cancer progression, and metastasis. The main features accompanying EMT are loss of epithelial characteristics of cells and acquisition of mesenchymal markers such as fibronectin, vimentin, and N-cadherin. As a result, EMT increases the invasiveness and migratory potential of tumor cells, supports their malignant transformation, and might lead to resistance of tumor cells to various therapeutic agents, especially in malignant gliomas. sushi repeat-containing protein, X-linked 2 (SRPX2) was first identified as sushi repeat protein up-regulated leukemia (SRPUL) and is a downstream molecule of the E2A-HLF fusion gene in t(17;19)-positive leukemia cells. SRPX2 contains 3 sushi domains and 1 hyaline domain name. A sushi domain name, also known as a complement control protein module or a short complement-like repeat, contains ~60 amino acids and is found in functionally diverse proteins, including regulators of the complement activation family, the GABA receptor, thyroid peroxidase, and the selectin family (OLeary et al.2004; Soares et al.2005). Sushi domains are thought to mediate specific proteinprotein and/or proteincarbohydrate binding and cellular adhesive functions (OLeary et al.2004; Soares et al.2005). SRPX2 also contains a hyaline (HYR) domain name, which probably corresponds to a newly discovered superfamily in the immunoglobulin fold. The HYR domains are often associated with sushi domains, and although the function of HYR domains is usually unclear, they are thought to be involved in cellular adhesion. Thus, accumulating information around the motifs found in SRPX2 suggest that SRPX2 is usually involved in cellular adhesion. SRPX2 was reported to contribute to the progression and metastasis of variety types of cancers, including gastric, colorectal, and gastrointestinal (Tanaka et al.2009,2012; Liu et al.2015). We hypothesize that SRPX2 also contributes to GBM progression and metastasis. Considering its role in cellular adhesion, SRPX2 is very likely to facilitate GBM metastasis by enhancing the EMT process. To test this hypothesis, we investigated SRPX2 expression levels in GBM tissue samples from 42 patients, as well as in cultured GBM cell lines. We also explored the expression level changes of EMT process markers in SRPX2 down-regulated GBM cells and were the first to document the involvement of SRPX2 in the EMT process and GBM metastasis. == Materials and Methods == == Patients == All investigations in this study were conducted according to the guidelines of the ethics committee of the Third Affiliated Hospital of Harbin Medical University, China. Informed consent was obtained from 42 patients with glioblastoma (GBM, WHO grade 4) who were randomly recruited. Fresh frozen primary GBM samples and paired normal brain tissues were obtained from the Department.Migration (e) and invasion (f) assays in U87MG cells (Vector, SRPX2 siRNA, SRPX2+PD098059, and control siRNA+PD098059) (**p<0.01) == Fig.7. metastasis. Our results revealed that GBM tumor samples Odiparcil from 42 patients expressed higher levels of SRPX2 than the control normal brain tissue samples. High-SRPX2 expression levels are correlated with poor prognosis in those patients, as well as resistance to temozolomide in cultured GBM cells. Up-regulating SRPX2 expression in cultured GBM cell lines facilitated invasiveness and migration of GBM cells, while down-regulating SRPX2 through RNA interference was inhibitory. These results suggest that SRPX2 plays an important role in GBM metastasis. Epithelial to mesenchymal transition (EMT) is one of the processes that facilitate GBM metastasis and resistance to chemotherapy. EMT marker expression was decreased in SRPX2 down-regulated GBM cells, and MAPK signaling pathway marker expression was also decreased when SRPX2 is knocked down in GBM-cultured cells. Blocking the MAPK signaling pathway inhibited GBM metastasis but did not inhibit cell invasion and migration in SRPX2 down-regulated cells. Our results indicate that SRPX2 facilitates GBM metastasis by enhancing the EMT process via the MAPK signaling pathway. Keywords:SRPX2, Glioblastoma, EMT, MAPK signaling pathway == Introduction == Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor in adults. It is classified by the World Health Organization as a grade IV tumor of the central nervous system (CNS) (WHO classification tumors of the CNS) (Kurosawa et al.1999). Until recently, complete surgical resection of these infiltrative tumors was virtually impossible. Concurrent adjuvant radiotherapy in combination with temozolomide (TMZ) is the standard of care for patients with newly diagnosed GBM, but less than 5 % of patients survive for longer than 5 years after diagnosis. GBM tumors are among the most resistant of tumors to radiation and cytotoxic chemotherapy. Epithelial to mesenchymal transition (EMT) is considered an important factor that contributes to GBM resistance by diminishing molecular targets (Laure and Bellacosa2005). EMT is a common process that takes part in organ development, wound healing, tissue remodeling, cancer progression, and metastasis. The main features accompanying EMT are loss of epithelial characteristics of cells and acquisition of mesenchymal markers Odiparcil such as fibronectin, vimentin, and N-cadherin. As a result, EMT increases the invasiveness and migratory potential of tumor cells, supports their malignant transformation, and might lead to resistance of tumor cells to various therapeutic agents, especially in malignant gliomas. sushi repeat-containing protein, X-linked 2 (SRPX2) was first identified as sushi repeat protein up-regulated leukemia (SRPUL) and is a downstream molecule of the E2A-HLF fusion gene in t(17;19)-positive leukemia cells. SRPX2 contains 3 sushi domains and 1 hyaline domain. A sushi domain, also known as a complement control protein module or a short complement-like repeat, contains ~60 amino acids and is found in functionally diverse proteins, including regulators of the complement activation family, the GABA receptor, thyroid peroxidase, and the selectin family (OLeary et al.2004; Soares et al.2005). Sushi domains are thought to mediate specific proteinprotein and/or proteincarbohydrate binding and cellular adhesive functions (OLeary et al.2004; Soares et al.2005). PRDM1 SRPX2 also contains a hyaline (HYR) domain, which probably corresponds to a newly discovered superfamily in the immunoglobulin fold. The HYR domains are often associated with sushi domains, and although the function of HYR domains is unclear, they are thought to be involved in cellular adhesion. Thus, accumulating information on the motifs found in SRPX2 suggest that SRPX2 is involved in cellular adhesion. SRPX2 was reported to contribute to the progression and metastasis of variety types of cancers, including gastric, colorectal, and gastrointestinal (Tanaka et al.2009,2012; Liu et al.2015). We hypothesize that SRPX2 also contributes to GBM progression and metastasis. Considering its role in cellular adhesion, SRPX2 is very likely to facilitate GBM metastasis by enhancing the EMT process. To test this hypothesis, we investigated SRPX2 expression levels.Fresh frozen primary GBM samples and paired normal brain tissues were obtained from the Department of Neurosurgery, Third Affiliated Hospital of Harbin Medical University. Glioma initiating cell isolation was performed as described previously (Jiao et al.2015). Epithelial to mesenchymal transition (EMT) is one of the processes that facilitate GBM metastasis and resistance to chemotherapy. EMT marker expression was decreased in SRPX2 down-regulated GBM cells, and MAPK signaling pathway marker expression was also decreased when SRPX2 is knocked down in GBM-cultured cells. Blocking the MAPK signaling pathway inhibited GBM metastasis but did not inhibit cell invasion and migration in SRPX2 down-regulated cells. Our results indicate that SRPX2 facilitates GBM metastasis by enhancing the EMT process via the MAPK signaling pathway. Keywords:SRPX2, Glioblastoma, EMT, MAPK signaling pathway == Introduction == Glioblastoma (GBM) is the most common and aggressive type of malignant primary brain tumor in adults. It is classified by the World Health Organization as a grade IV tumor of the central nervous system (CNS) (WHO classification tumors of the CNS) (Kurosawa et al.1999). Until Odiparcil recently, complete surgical resection of these infiltrative tumors was virtually impossible. Concurrent adjuvant radiotherapy in combination with temozolomide (TMZ) is the standard of care for patients with newly diagnosed GBM, but less than 5 % of patients survive for longer than 5 years after diagnosis. GBM tumors are among the most resistant of tumors to radiation and cytotoxic chemotherapy. Epithelial to mesenchymal transition (EMT) is considered an important factor that contributes to GBM resistance by diminishing molecular targets (Laure and Bellacosa2005). EMT is a common process that takes part in organ development, wound healing, tissue remodeling, cancer progression, and metastasis. The main features accompanying EMT are loss of epithelial characteristics of cells and acquisition of mesenchymal markers such as fibronectin, vimentin, and N-cadherin. As a result, EMT increases the invasiveness and migratory potential of tumor cells, supports their malignant transformation, and might lead to resistance of tumor cells to various therapeutic agents, especially in malignant gliomas. sushi repeat-containing protein, X-linked 2 (SRPX2) was first identified as sushi repeat protein up-regulated leukemia (SRPUL) and is a downstream molecule of the E2A-HLF fusion gene in t(17;19)-positive leukemia cells. SRPX2 contains 3 sushi domains and 1 hyaline domain. A sushi domain, also known as a complement control protein module or a short complement-like repeat, contains ~60 amino acids and is found in functionally diverse proteins, including regulators of the complement activation family, the GABA receptor, thyroid peroxidase, and the selectin family (OLeary et al.2004; Soares et al.2005). Sushi domains are thought to mediate specific proteinprotein and/or proteincarbohydrate binding and cellular adhesive functions (OLeary et al.2004; Soares et al.2005). SRPX2 also contains a hyaline (HYR) domain, which probably corresponds to a newly discovered superfamily in the immunoglobulin fold. The HYR domains are often associated with sushi domains, and although the function of HYR domains is unclear, they are thought to be involved in cellular adhesion. Thus, accumulating information on the motifs found in SRPX2 suggest that SRPX2 is involved in cellular adhesion. SRPX2 was reported to contribute to the progression and metastasis of variety types of cancers, including gastric, colorectal, and gastrointestinal (Tanaka et al.2009,2012; Liu et al.2015). We hypothesize that SRPX2 also contributes to GBM progression and metastasis. Considering its role in cellular adhesion, SRPX2 is very likely to facilitate GBM metastasis by enhancing the EMT process. To test this hypothesis, we investigated SRPX2 expression levels in GBM tissue samples from 42 patients, as well as in cultured GBM cell lines. We also explored the expression level changes of EMT process markers in SRPX2 down-regulated GBM cells and were the first to document the involvement of SRPX2 in the EMT process and GBM metastasis. == Materials and Methods == == Patients == All investigations in this study were conducted according to the guidelines of the ethics committee of the Third Affiliated Hospital of Harbin Medical University or college, China. Informed consent was from 42 individuals with glioblastoma (GBM, WHO grade 4).